P&G’s Intrinsa For Female Sexual Dysfunction To Get Cmte. Review Dec. 2
This article was originally published in The Pink Sheet Daily
If recommended by FDA’s Reproductive Health Drugs Advisory Committee, Intrinsa would be on a path for approval in December or January. The testosterone patch could be the first treatment for female sexual dysfunction.
You may also be interested in...
NDA for testosterone patch to treat reduced sexual desire in surgically menopausal women was submitted in early summer. First female sexual dysfunction agent filed at FDA is "next major opportunity" for P&G's pharmaceutical business, CFO Daley tells Banc of America Securities conference.
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.